|
|
Four Analytes that can Provide Early Detection of Epithelial Ovarian Cancer
May 11, 2005, 10:39, Reviewed by: Dr.
|
|
With researchers from Yale University and George Washington University the Wards, husband and wife researchers, identified that leptin, prolactin, osteopontin, and insulin-like growth factor-II can make possible the early detection of EOC before onset of symptoms.
|
By Nevada Cancer Institute,
Research co-authored by David C. Ward, Ph.D. and Patricia Bray-Ward, Ph.D. of the Nevada Cancer Institute has identified four analytes that can provide early detection of epithelial ovarian cancer (EOC) in women before they present with physical symptoms. The breakthrough study "Serum Protein Markers for Early Detection of Ovarian Cancer" was reported in the Proceedings of the National Academy of Sciences on May 9, 2005.
Ovarian cancer is one of the leading cancers and detection before symptoms are manifested is difficult. With researchers from Yale University and George Washington University the Wards, husband and wife researchers, identified that leptin, prolactin, osteopontin, and insulin-like growth factor-II can make possible the early detection of EOC before onset of symptoms.
About David C. Ward, Ph.D.
David C. Ward was appointed as the Deputy Director of the Nevada Cancer Institute (NVCI) in May of 2004. As the deputy director, Dr. Ward works closely with Nicholas Vogelzang, MD, FACP the Director of NVCI, to coordinate the institute's scientific research efforts in Basic Translational Research, Population Science and Drug Development. Dr. Ward is internationally recognized for his pioneering research in the fields of molecular cytogenetics, cancer genetics, virology and optical imaging technology. He has received numerous awards, both nationally and internationally, including election to the National Academy of Sciences of the USA. He has co-authored over 300 scientific publications and has served on grant review panels in the US, Canada and England for many years. Dr. Ward is also a co-founder of five biotechnology companies, three of which are publicly traded on national stock exchanges.
Dr. Ward earned his B.S. in Microbiology from Memorial University of Newfoundland, Canada; M.Sc. in Biochemistry from the University of British Columbia, Vancouver; and his Ph.D. in Biochemistry from Rockefeller University, New York. After a postdoctoral fellowship at the Imperial Cancer Research Fund in London, England, Dr. Ward joined the faculty of Yale University School of Medicine in 1971, where he remained in the Departments of Genetics and Molecular Biophysics and Biochemistry until he joined NVCI.
About Patricia Bray-Ward, Ph.D.
Patricia Bray-Ward, Ph.D. is a renowned researcher in the area of molecular cytogenetics, cancer genetics, molecular techniques development and optical imaging technology. She has been a research partner of David C. Ward, Ph.D. for more than a decade, and together they have made pioneering scientific discoveries that have resulted in multiple patents.
Dr. Bray-Ward came to the Nevada Cancer Institute from Yale University, where she was a distinguished researcher in the Department of Genetics for 11 years. Her career includes nearly a decade as a Predoctoral, Postdoctoral, and then Senior Fellow at the National Institutes of Health (NIH). The focus area of her research is technology development and translational research. She has published numerous articles about mechanisms that enable the detection of disease proclivities and presence.
Dr. Bray-Ward earned her B.A. in Life Sciences from Queens University in Ontario, Canada and her Ph.D. in Genetics from George Washington University, where her thesis research was completed at the NIH under the guidance of Dr. Marshall Nirenberg. 
- The breakthrough study "Serum Protein Markers for Early Detection of Ovarian Cancer" was reported in the Proceedings of the National Academy of Sciences on May 9, 2005.
www.nevadacancerinstitute.org
About Nevada Cancer Institute
The Nevada Cancer Institute (NVCI) is the official cancer institute for the State of Nevada. NVCI's mission is to develop a comprehensive cancer research institute staffed by the finest scientists, clinicians and caregivers, to provide hope for the community through education, support and patient-centered care and striving for a future without cancer through innovative translational research in basic, clinical and population science. NVCI has raised $50 million in private community financial support, with additional support of a repayable $50 million construction bond for NVCI's 142,000 square foot flagship research and care facility in the Summerlin district of Las Vegas. The facility is scheduled to open later this summer. For more information on NVCI, please visit www.nevadacancerinstitute.org
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
Top of Page
|
|
|
|
